ALYREF was originally described as a transcriptional coactivator of the T-cell receptor α gene by binding LEF-1 and acute myeloid leukemia (AML)-1 transcription factors to form an enhancer-stimulating complex [29]. Here, ALYREF is linked to acute myeloid leukemia.